Stunning News In Pancreatic Cancer Research

When Gleevec, the very first targeted therapeutic came out, there was a mad rush in the pharmaceutical industry to mine the genome for potential “magic bullet” targets.  In Gleevec’s case, it was able to inhibit the BCR-ABL fusion kinase, and turn a deadly disease into a manageable chronic condition.  But with a disease as complex as pancreatic cancer, the prospect of finding a “magic bullet” target seemed remote.

This week however, scientists at the University of Michigan (publishing in the Journal of Clinical Investigation) were able to demonstrate that by inhibiting the gene KRAS in a mouse model, precancerous lesions and tumors could be destroyed.  KRAS plays a critical role in the early stages of pancreatic cancer (as shown in the KEGG pathway diagram below) and this study demonstrates that KRAS could make a very promising drug discovery target.

As anyone in the pharmaceutical industry will tell you though, there’s a lot of work between identifying a promising target, and having a drug ready for clinical trials.  But this is a promising start to validating KRAS as a potential target.


About Mark Fortner

I write software for scientists doing drug discovery and cancer research. I'm interested in Design Thinking, Agile Software Development, Web Components, Java, Javascript, Groovy, Grails, MongoDB, Firebase, microservices, the Semantic Web Drug Discovery and Cancer Biology.
This entry was posted in Cancer Research, Drug Development, pancreatic cancer, Science Blogging, Uncategorized and tagged , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s